These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 9797019

  • 1. Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor.
    Goss PE.
    Breast Cancer Res Treat; 1998; 49 Suppl 1():S59-65; discussion S73-7. PubMed ID: 9797019
    [Abstract] [Full Text] [Related]

  • 2. Vorozole.
    Wiseman LR, Spencer CM.
    Drugs Aging; 1997 Sep; 11(3):245-50; discussion 251-2. PubMed ID: 9303282
    [Abstract] [Full Text] [Related]

  • 3. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
    Goss PE, Winer EP, Tannock IF, Schwartz LH.
    J Clin Oncol; 1999 Jan; 17(1):52-63. PubMed ID: 10458218
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological and clinical profile of anastrozole.
    Lønning PE, Geisler J, Dowsett M.
    Breast Cancer Res Treat; 1998 Jan; 49 Suppl 1():S53-7; discussion S73-7. PubMed ID: 9797018
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Emerging role of aromatase inhibitors in the treatment of breast cancer.
    Harvey HA.
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacology of vorozole.
    Wouters W, Van Ginckel R, Krekels M, Bowden C, De Coster R.
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):617-21. PubMed ID: 8386540
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.
    de Jong PC, van de Ven J, Nortier HW, Maitimu-Smeele I, Donker TH, Thijssen JH, Slee PH, Blankenstein RA.
    Cancer Res; 1997 Jun 01; 57(11):2109-11. PubMed ID: 9187104
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE, Clark RM, Ambus U, Weizel HA, Wadden NA, Crump M, Walde D, Tye LM, De Coster R, Bruynseels J.
    Clin Cancer Res; 1995 Mar 01; 1(3):287-94. PubMed ID: 9815984
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.
    Dowsett M, Doody D, Miall S, Howes A, English J, Coombes RC.
    Breast Cancer Res Treat; 1999 Jul 01; 56(1):25-34. PubMed ID: 10517340
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A, Howell SJ, Clarke R, Anderson E.
    J Steroid Biochem Mol Biol; 2001 Dec 01; 79(1-5):227-37. PubMed ID: 11850229
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.